<- Go Home
CERo Therapeutics Holdings, Inc.
CERo Therapeutics Holdings, Inc., an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer. Its lead development candidate is CER-1236, an autologous T cell therapy candidate for the treatment of hematologic malignancies and solid tumors. The company was incorporated in 2021 and is based in South San Francisco, California.
Market Cap
$166.0K
Volume
308.5K
Cash and Equivalents
$3.3M
EBITDA
-$16.7M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
N/A
Profit Margin
N/A
52 Week High
$895.40
52 Week Low
$0.06
Dividend
N/A
Price / Book Value
-0.01
Price / Earnings
-0.00
Price / Tangible Book Value
-0.01
Enterprise Value
$6.6M
Enterprise Value / EBITDA
-0.44
Operating Income
-$17.0M
Return on Equity
684.16%
Return on Assets
-156.89
Cash and Short Term Investments
$3.3M
Debt
$1.2M
Equity
-$1.6M
Revenue
N/A
Unlevered FCF
-$8.6M
Sector
Biotechnology
Category
N/A